NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc0
We present a Bayesian machine learning framework integrating genetic, molecular, and wearable sensor biomarkers for precision medicine in Parkinson’s disease. Using PPMI (4,775 patients, 14,473 longitudinal records) and LRRK2 Consortium (627 individuals, 2,958 biological specimens), we demonstrate: (1) LRRK2 G2019S confers 1.92-fold PD risk (individual-level χ 2 = 36.6, p = 1.4 × 10 − 9 ; sex-adjusted OR=2.73) with carriers exhibiting 4.35-point higher motor severity (95% CI [1.95, 6.47], rank-biserial r = −0.270); (2) Wearable IMU sensors quantified Arm Swing Asymmetry (27% prevalence, n = 178) and Dual-Task Cost (14.87% degradation, t = 14.98, p < 0.001), enabling continuous cognitive-motor network monitoring; (3) Molecular markers phospho-LRRK2 ( n = 884) and CSF ε -synuclein seed amplification ( n = 145) provide therapeutic monitoring and differential diagnosis; (4) Prodromal screening identified olfactory dysfunction (50.2%, n = 5, 122) and RBD (37.5%, n = 1, 548). Bayesian clustering via Evidence Lower Bound selection achieved Silhouette=0.535 with bootstrap stability (Jaccard=0.769), outperforming alternatives (0.170–0.452). Risk prediction model: AUC=0.717, calibration slope=1.197. This reproducible framework (complete code-result traceability, TRIPOD+AI compliant) enables mechanism-targeted precision medicine aligned with SDGs 3, 9, 10.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.